Evidence map›Paper›PMID 33811272›Full record

ArticleJournal of cancer research and clinical oncology2021

Tau oligomers accumulation sensitizes prostate cancer cells to docetaxel treatment.

Stefano Martellucci, Letizia Clementi, Samantha Sabetta, Paola Muzi, Vincenzo Mattei, Mauro Bologna, Adriano Angelucci

Open access · hybridAbstract read
In one paragraph

Article in Journal of cancer research and clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Tau Isoforms: Gaining Insight intoInternational journal of molecular sciences · 2022
    Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Stefano MartellucciDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio, 67100, L'Aquila, Italy.
Letizia ClementiDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio, 67100, L'Aquila, Italy.
Samantha SabettaDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio, 67100, L'Aquila, Italy.
Paola MuziDepartment of Life, Health and Environmental Sciences, University of L'Aquila, 67100, L'Aquila, Italy.
Vincenzo MatteiBiomedicine and Advanced Technologies Rieti Center "Sabina Universitas", 02100, Rieti, Italy.
Mauro BolognaDepartment of Life, Health and Environmental Sciences, University of L'Aquila, 67100, L'Aquila, Italy.
Adriano AngelucciDepartment of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio, 67100, L'Aquila, Italy. adriano.angelucci@univaq.it.ORCID http://orcid.org/0000-0002-8755-1889
University of L'Aquila · ITIMT School for Advanced Studies Lucca · IT

Funding

Ministero dell'Istruzione, dell'Università e della Ricerca DOT13SR6G7
6 · The paper itself

Abstract

purposeHuman tau is a highly dynamic, multifunctional protein expressed in different isoforms and conformers, known to modulate microtubule turnover. Tau oligomers are considered pathologic forms of the protein able to initiate specific protein accumulation diseases, called tauopathies. In our study, we investigated the potential association between autophagy and tau oligomers accumulation and its role in the response of prostate cancer cells to docetaxel.

methodsWe evaluated in vitro the expression of tau oligomers in prostate cancer cell lines, PC3 and DU145, in presence of autophagy inhibitors and investigated the role of tau oligomers accumulation in resistance to docetaxel treatment.

resultsTau protein was basally expressed in prostate cancer lines as several monomeric and oligomeric forms. The pharmacologic inhibition of autophagy induced in cancer cells the accumulation of tau protein, with a prevalent expression of oligomeric forms. Immunofluorescence analysis of untreated cells revealed that tau was visible mainly in dividing cells where it was localized on the mitotic spindle. Inhibition of autophagy determined an evident upregulation of tau signal in dividing cells and the presence of aberrant monoastral mitotic spindles. The accumulation of tau oligomers was associated with DNA DSB and increased cytotoxic effect by docetaxel.

conclusionsOur data indicate that autophagy could exert a promoting role in cancer growth and during chemotherapy facilitating degradation of tau protein and thus blocking the antimitotic effect of accumulated tau oligomers. Thus, therapeutic strategies aimed at stimulating tau oligomers formation, such as autophagy inhibition, could be an effective adjuvant in cancer therapy.

Indexed as

AutophagyGene Expression Regulation, NeoplasticProtein MultimerizationAntineoplastic AgentsApoptosisCell ProliferationDocetaxelHumansMaleProstatic Neoplasmstau ProteinsTumor Cells, CulturedAntineoplastic AgentsDocetaxeltau ProteinsAutophagyCancer TherapyDocetaxelMitosisProstate CancerTau oligomer

Identifiers

PMID33811272
PMCPMC8164592
OpenAlexW3148622421

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.